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Abstract
The aim of this study was to determine the demographic characteristics of methicillin-resistant Staphylococcus aureus (MRSA) carriers in
the community, to assess their risk factors and possible past hospitalization history and to describe the different resistance phenotypes
of community isolates of S. aureus. Data were collected over the course of 16 months (from June 2005 to September 2006) in the Pays
de la Loire region of France by MedQual, a network of private biological analysis laboratories. This work was based solely on the analy-
sis of strains isolated in the community as opposed to isolates from private facilities such as nursing homes or hospitals. The antimicro-
bial susceptibility results for a total of 313 MRSA isolates were included in this study. The isolates were most frequently recovered
from skin and soft tissue infections (41.2%), urine (38.3%) and genital samples (8.3%). We distinguished 36 patients without classical risk
factors (WRF), such as demographic individual medical, healthcare exposure, carried MRSA, from the other 277 patients with at least
one risk factor (RF). WRF MRSA patients were younger than RF patients and an infection was more often found among WRF patients.
MRSA strains isolated from RF patients were resistant to oﬂoxacin in 81.1% of cases, whereas only 50% of the MRSA strains isolated
from WRF patients were resistant (p <0.001). Nine resistance phenotypes were observed among the 313 MRSA strains. MRSA
resistance proﬁles in the community have evolved in recent years. Therefore, it is necessary to study the resistance phenotypes of the
circulating strains in order to adapt therapeutic care in the community.
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Introduction
Staphylococcus aureus is an important pathogen in the com-
munity as a whole as well as in hospitals. This bacterium
has shown a remarkable capacity for frequent acquisition of
various resistances to many antibiotics. Methicillin resistance
among S. aureus species was ﬁrst described in 1961 in the
UK [1]. Since the 1980s, methicillin-resistant S. aureus
(MRSA) strains have spread throughout Europe, and subse-
quently through the USA, becoming endemic pathogens in
hospitals. The evolution of S. aureus resistance to antibiotics
was thus especially monitored in hospitals [2]. Infections
with S. aureus have become one of the most frequent
hospital-acquired infections and have begun to spread world-
wide, but the prevalence of these infections varies in differ-
ent countries [3–7].
Whereas the susceptibility of S. aureus in the community
has been well documented in the USA, few studies have
focused their efforts on France. However, as MRSA has high
pathogenic potential and its commensal nature predisposes it
to extra-hospital spread [8,9], studies that incorporate the
analysis of data gathered from individuals in many parts of
the world are warranted.
Community-acquired MRSA strains have two possible ori-
gins [10]. They can originate in the hospital, where they are
carried by healthcare workers and by hospitalized patients,
and they can be transferred from healthcare facilities to
nursing homes and those receiving care at home.
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Carrying and spreading hospital-acquired MRSA in
the community primarily occurs among patients with risk
factors (e.g. long-term catheters, chronic dialysis, previous
hospitalizations, and chronic cutaneous lesions) and also the
family members and friends of these patients [10–12].
These MRSA strains are often resistant to antibiotics of
many families (e.g. aminoglycosides, macrolides and quino-
lones). The proﬁles of resistance to antibiotics are usually
the same in private settings as in hospitals. They arise
under the selective pressure applied by antibiotic therapy
and diffuse along with these strains inside the hospital,
especially in units with high concentrations of patients with
high infectious risks and long hospitalization periods, and in
patients requiring invasive procedures. MRSA strains causing
serious infections can be isolated among patients without
risk factors and without previous hospitalization [13].
Over the last 10 years, MRSA epidemiology in the com-
munity has changed. In France, these community-acquired
strains appeared in 1999, but their incidence remains insufﬁ-
ciently evaluated. The corresponding infections especially
occur among children and young adults, unlike what is
observed in hospitals. Community-acquired MRSA strains are
responsible for cutaneous infections and sometimes necrotiz-
ing pneumonia [14]. Antibiotic resistance proﬁles are likewise
different, as they often show resistance to one or two anti-
biotic families. The isolates of these MRSA strains can gener-
ate difﬁculties in patient care, with respect to both therapy
and control of diffusion [15].
A retrospective study conducted by the antibiotic resis-
tance survey network ONERBA in 2000–2003 in France
[16] found that 0.4–1.0% of MRSA isolates had an antibiotic
susceptibility pattern previously associated with the produc-
tion of Panton-Valentine leukocidin (PVL) toxin. Moreover,
while monitoring antibiotic resistance of S. aureus in 2004
in the Pays de la Loire region of France by MedQual, a net-
work of private biological analysis laboratories (BAL), 1686
S. aureus strains were collected, 259 of which were MRSA.
In view of this high incidence rate (15.4%), an epidemiologi-
cal study, both prospective and multicentre, was performed.
The objective of this work was to determine the demo-
graphic characteristics of MRSA carriers in the community
and to assess their risks factors and possible history past hos-
pitalization. This study also sought to describe the different
S. aureus resistance phenotypes of community-isolated strains.
Methodology
A total of 175 BAL in the Pays de la Loire region in France
were asked to participate in this study. Representation within
the network was anonymously evaluated using Healthcare
System data at both the regional and departmental levels.
Participation in this network was voluntary.
The data were collected over 16 months, from June 2005
to September 2006. Staphylococcus aureus antibiograms were
performed using a gel diffusion test or an automated broth dilu-
tion method (API, Vitek 2), according to the recommendations
of the Antibiogram Committee of the French Microbiology
Society (CASFM) [www.sfm.asso.fr] [2005–2006].
Antibiograms rendered anonymous were regularly
transmitted to the MedQual centre and were accompanied
by administrative information concerning the patient (e.g.
age, gender, and sampling date).
Patients with community-acquired MRSA were analysed,
which included out-patients and patients from non-medical
nursing homes. All patients from private hospitals, medical
nursing homes, and emergency departments were excluded.
Doubles were deﬁned as two isolates from the same sample.
Isolates that were susceptible to gentamicin, tobramycin,
and ﬂuoroquinolones and resistant to fusidic acid and kana-
mycin, were tested for the structural types of mec elements
(SCCmec) and PVL genes [17,18]. After DNA extraction, the
presence of the mecA gene was conﬁrmed by PCR. Struc-
tural types of SCCmec were determined using multiplex
PCR. The electrophoresis patterns were compared with
those of the major characterized structural types of mec
cassettes to determine the type of the studied strains [17].
The primer sequences used for PVL gene characterization
(luk-PV-1 and luk-PV-2) have been described by Lina et al. [18].
A questionnaire (Appendix 1) was answered for all of the
patients included in this study. This questionnaire inquired
about individual medical factors, previous medical care or
hospitalization, clinical consequences (colonization/infection)
and therapeutic care. These data were reported by the
patient’s general practitioner (GP) by phone, either to the
biologist who took the sample or to the MedQual centre.
Data were entered and analysed with the assistance of the
Epi Info computer database (version 6.04c; Centers for Dis-
ease Control and Prevention, Atlanta, GA, USA) within Med-
Qual. The v2 test, Fisher’s two-failed test for proportions,
and Student’s t-test were used to calculate statistical signiﬁ-
cance.
Results
Sixty-four laboratories sent their results to be analysed,
which corresponds to a c. 37% participation rate. This
MedQual network represented 41.32% of the bacteriological
activity in the Pays de la Loire region. Five hundred and ﬁfty-
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two MRSA antibiograms were collected during the study
period, but only 313 susceptibility tests were accompanied
by a questionnaire and could be included in the study. The
remaining 239 antibiograms could not be included because
the epidemiological data were missing (absence of an answer
from the GP, impossibility of joining the GP). The average
age of the patients was 65 ± 25 years; age was equally
distributed among the two genders.
The incidence rate of oxacillin resistance was 15% (552
out of 3667 S. aureus isolates). The isolates were most fre-
quently recovered from skin and soft tissue infections
(41.2%), urine (38.3%), genital samples (8.3%) and sputum
(1.9%). Other pathological products represented 10.3%,
essentially from the ear-nose-throat sphere. The number of
MRSA isolates from urine was high, particularly from older
patients.
Among the 313 patients analysed in this study, 36
(11.5%) had none of the risk factors queried in the ques-
tionnaire, such as home care, hospitalization during the pre-
ceding 12 months, and the presence of chronic cutaneous
lesions. We distinguished these 36 patients carrying MRSA
without classical risk factors (WRF), from the other
patients who carried MRSA and had at least one risk factor
(RF). Table 1 shows the distribution of MRSA isolates
among these two populations with respect to the sampling
site. Among RF patients, MRSA were primarily found in
urine and skin and soft tissue infections. In WRF patients,
MRSA were isolated from skin and soft tissue infections
and from genital samples.
The characteristics of both WRF and RF MRSA carriers
are described in Table 2. WRF MRSA patients were younger
than RF patients (47.9 ± 27 vs. 67.8 ± 23 years, p <0.0001).
An infection was more often found among WRF patients
(OR 3.6, 95% CI 1.5–8.9, p <0.001). The most frequent RFs
were home care, hospitalization during the preceding
12 months and presence of chronic cutaneous lesions.
Antibiogram analysis
The percentage of isolates intermediate and resistant to dif-
ferent antibiotics among the 313 samples was determined
and the presence of risk factors was assessed in each case.
The MRSA isolates from RF patients were resistant to oﬂox-
acin in 81.1% of cases, whereas only 50% of the MRSA from
WRF patients were resistant to oﬂoxacin (p <0.001).
Approximately 33.3% of the MRSA isolates from the WRF
patients were intermediate or resistant to fusidic acid vs.
14.6% of MRSA from RF patients (p <0.01).
Resistance phenotypes of the MRSA isolates
Nine resistance phenotypes were identiﬁed by taking into
account the response of S. aureus to oxacillin, gentamicin,
tobramycin, oﬂoxacin and macrolides (Table 3). Phenotypes
2 (31%) and 3 (23.3%) were the most prevalent, with
resistance to oxacillin, tobramycin and quinolones but with
different susceptibilities to the macrolides.
Forty-nine MRSA isolates (15.7%) were resistant to
quinolones only, apart from oxacillin (phenotype 7), and 28
MRSA isolates (8.9%) were resistant to oxacillin only (pheno-
type 9). Among these 28 isolates, ten were from patients
hospitalized within the year prior to the sampling, with four
coming from patients receiving home care and seven from
patients with chronic cutaneous lesions. The remaining seven
TABLE 1. Distribution of methicillin-resistant Staphylococcus
aureus (MRSA) strains among patients without risk factors













Skin and soft tissue
infections
41.2 36 42 0.5
Urine 38.3 17 41 < 0.005
Genital samples 8.3 33 5 < 0.0001
Respiratory samples
(sputum)
1.9 - 2 -
Other* 10.8 14 10 0.68
TOTAL 100 100 100
Other*: Ear-Nose-Throat- sphere, Faeces.
WRF**: patients without risk factor.
RF***: patients with risk factor.
TABLE 2. Characteristics of the 313 patients carrying meth-
icillin-resistant Staphylococcus aureus (MRSA) strains, by




N = 36 N = 277
Age (years) 47.9 ± 27 67.8 ± 23 <0.0001
Male 36% 44% 0.37
Previous MRSA carriage - 19%
Hospitalization over the last 12 months - 52%
Healthcare worker - 4%
Healthcare worker among relatives - 9%
Chronic cutaneous lesions - 37%
Respiratory disease - 14%
Presence of an indwelling device - 18%
Home care - 49%
Strain responsible for an infection 67% 51% <0.001
Treatment with antibiotics 81% 73% 0.32
WRF**: patients without risk factor.
RF***: patients with risk factor.
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MRSA isolates were from patients with no previous hospital-
ization or risk factors.
Table 4 presents the eight previously described phenotypes
detected in the 36 WRF patients (phenotypes 2–9). Among
the WRF patients, phenotype 2 (25%), which was resistant to
tobramycin, oﬂoxacin and erythromycin, and phenotype 9
(19.4%), which was resistant to oxacillin, were the most
frequent. Interestingly, no phenotype 1 strains were found in
the WRF population. Among the 11 MRSA isolates of pheno-
type 8, eight had a characteristic MRSA PVL phenotype. These
MRSA isolates had the mecA gene, the SCCmec type IV and
were negative for PVL with the exception of two that pro-
duced the PVL toxin. These strains were all isolated from RF
patients.
Discussion
Few epidemiological studies concerning MRSA in the French
community have been published. The originality of this work
is based on the fact that the only strains analysed were those
isolated from the community directly as opposed to those
from private facilities such as nursing homes or hospitals. This
study recruited the participation of 64 regional laboratories
and represents more than 40% of the bacteriological activity
in the Pays de la Loire region over a 16-month period.
There are two widely prevalent MRSA strains: HA-MRSA,
corresponding to strains found in hospitals, and CA-MRSA,
corresponding to community-acquired strains [10,19].
Classiﬁcation into CA-MRSA was achieved for those cases
that occurred in the absence of risk factors related to
healthcare. CA-MRSA strains have speciﬁc virulence charac-
teristics and target populations (e.g. PVL-related virulence,
young subjects) and cause well-deﬁned clinical manifestations
(e.g. cutaneous and/or very serious pulmonary manifesta-
tions) [10,20–30]. In this survey we observed MRSA strains
isolated from the community, but from patients without the
characteristic manifestations of CA-MRSA described above.
The way in which we analysed our results did not allow
for classiﬁcation of the isolates into the two populations of
HA-MRSA and CA-MRSA. Instead, MRSA isolates were
divided into two sub-populations, depending on whether or
not they were associated with a risk factor. The majority of
MRSA isolates were found among patients with risk factors
(88.5%), whereas 11.5% of the isolates were from patients
who had not been in contact with the healthcare system
and/or exposed to antibiotics during the year prior to the
survey.
Recently, a study in Denmark [27] described a ten-fold
increase in the proportion of MRSA in the community since
2002. Similar to our study, they identiﬁed the two MRSA
populations described before (HA-MRSA and CA-MRSA).
They also noted resistance to three or several antibiotic
classes in 47% of the strains [27]. We observed a similar
antibiotic resistance pattern in 65% of the MRSA isolated in
the community.
Our survey corroborates data from prior studies [28,29];
together they suggest that it is risky to consider only the
absence of risk factors to establish the nature of an MRSA
strain, as this can lead to an underestimation of the
importance of community-acquired MRSA. Our study also is
in agreement with the previous studies in that the distinction
TABLE 3. Distribution of the resis-
tance phenotypes of MRSA isolates
from the 313 patients
Phenotype (%) Oxacillin Gentamicin Tobramycin Oﬂoxacin Macrolide
1 (n = 7) 2.2 R R R R R
2 (n = 97) 31.0 R S R R R
3 (n = 73) 23.3 R S R R S
4 (n = 11) 3.5 R S R S R
5 (n = 20) 6.4 R S R S S
6 (n = 17) 5.5 R S S R R
7 (n = 49) 15.7 R S S R S
8 (n = 11) 3.5 R S S S R
9 (n = 28) 8.9 R S S S S
TABLE 4. Distribution of the resis-
tance phenotypes among methicil-
lin-resistant Staphylococcus aureus
(MRSA) isolates from the 36 WRF
patients
Phenotype (%) Oxacillin Gentamicin Tobramycin Oﬂoxacin Macrolide
1 (n = 0) 0 R R R R R
2 (n = 9) 25.0 R S R R R
3 (n = 5) 13.9 R S R R S
4 (n = 3) 8.3 R S R S R
5 (n = 3) 8.3 R S R S S
6 (n = 2) 5.6 R S S R R
7 (n = 2) 5.6 R S S R S
8 (n = 5) 13.9 R S S S R
9 (n = 7) 19.4 R S S S S
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between CA-MRSA and HA-MRSA is not as clear as during
the emergence of CA-MRSA during the later 1990s. To char-
acterize the CA-MRSA responsible for cutaneous and/or pul-
monary infections and for producing the PVL toxin, it would
be interesting to specify its PVL status.
Of the MRSA carriers surveyed here, 52% were hospi-
talized sometime within the past 12 months, and half of
the carriers received home care. Almost 30% of our pop-
ulation were both hospitalized within the past year and
received home care. Less than 10% of the patients worked
or had someone among their contacts working at the
hospital, and 18% of the patients were carriers of an
invasive device.
Nearly 80% of our population had contact with the hospi-
tal environment, conﬁrming the relevance of the risk factors
associated with a hospital setting. Of the remaining 20%, only
30% had chronic cutaneous lesions and 7% had a respiratory
disease. Only two patients presented with both these risk
factors. Almost 5% of patients presented with a cutaneous
lesion and 3% presented with respiratory disease as their
unique risk factor.
Among the WRF patients, the bacteria isolated in this
study were primarily found in genital samples (33%), in skin
and soft tissue infections (36%), and in urine (17%).
It would be necessary to investigate mechanisms by which
to control the infections, as it is unknown if treatment with
antibiotics is required, or if the infection will resolve with
changes in hygienic practices. It is also of interest to study
treatment options for pregnant women.
We described nine resistance phenotypes among the 313
MRSA isolates based on resistance to major antibiotics. No
resistance phenotype allows a distinction between the two
populations. Among the 36 strains isolated from WRF
patients, 25% were resistant to at least four antibiotic fami-
lies, and 8.9% were resistant to oxacillin only. Only eight of
the 313 total isolates presented a PVL-typical antibiotic resis-
tance pattern, sensitive to ﬂuoroquinolones, tobramycin and
gentamicin, and resistant to fusidic acid [17].
The two strains producing PVL were isolated from RF
patients, and these patients also showed chronic cutaneous
lesions. Among WRF patients, three strains showed the typi-
cal MRSA PVL phenotype, but none was a PVL producer.
Patient care methods have signiﬁcantly changed over time,
where the length of hospital stay has been shortened in an
effort to promote home care. As S. aureus strains with
MRSA resistance proﬁles have evolved in recent years in the
community, it is necessary to study resistance phenotypes of
the circulating strains in order to adapt therapeutic care to
treat effectively the infections they cause. The development
of a monitoring system for S. aureus isolated in the commu-
nity in the Grand Ouest region of France, coordinated by
the MedQual centre, will allow us to conﬁrm these data.
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1. Previous MRSA carriage ? Yes h No h
2. Does the patient have a risk factor of colonization
or infection with MRSA?
Hospitalization over the last 12 months Yes h No h
Healthcare worker Yes h No h
Healthcare worker among relatives Yes h No h
Chronic cutaneous lesions Yes h No h
Respiratory disease Yes h No h
Presence of an indwelling device Yes h No h
Home care Yes h No h
3. Strain responsible for
an infection? Yes h No h
A colonization? Yes h No h
4. Has the patient received an antibiotic treatment for the
infection or the colonization?
Yes h No h
If Yes:
Antibiotic 1: ……… Duration of treatment: ……
Antibiotic 2: ……… Duration of treatment: ……
Antibiotic 3: ……… Duration of treatment: ……
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